Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
Curr Drug Targets
; 21(10): 1026-1033, 2020.
Article
em En
| MEDLINE
| ID: mdl-32334501
ABSTRACT
Notwithstanding important advances in the treatment of epithelial ovarian cancer (EOC), this disease is still a leading cause of global high mortality from gynecological malignancies. Recurrence in EOC is inevitable and it is responsible for poor survival rates. There is a critical need for novel effective biomarkers with improved accuracy compared to the standard carbohydrate antigen-125 (CA-125) for follow-up. The human epididymis protein 4 (HE4) is used for early detection of EOC (ROMA algorithm) as well as for predicting optimal cytoreduction after neoadjuvant chemotherapy and survival outcomes. Notably, the emerging HE4 is a promising prognostic biomarker that has displayed better accuracy in various recent studies for detecting recurrent disease. In this mini-review, we discussed the potential of HE4 as an accurate predictor of EOC recurrence.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Carcinoma Epitelial do Ovário
/
Proteína 2 do Domínio Central WAP de Quatro Dissulfetos
/
Recidiva Local de Neoplasia
Tipo de estudo:
Prognostic_studies
/
Screening_studies
Limite:
Female
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article